healthy subjects
Conditions
Interventions
1:Phase 1: broken pieces
Phase 2: traditional slices
2:Phase 1: traditional slices Phase 2: broken pieces
Sponsors
Clinical Pharmacology Institution, Xiang Ya Hospital, Central South University
Eligibility
Sex/Gender
All
Age
18 Years to 28 Years
Inclusion criteria
Inclusion criteria: 1. healthy volunteers, aged 18 to 40 years, including boundary values; the age difference in a group no more than 10 years; 2. The body mass index (BMI) at 1924 kg/m2 was greater than the weight of 50 kg, including the boundary value; 3. No abnormal findings in physical examination; 4. No history of drug allergy; 5. No history of drink alchol and tobacco; 6. The subjects volunteered to participate in the trial and were willing to sign the informed consent in accordance with the procedures specified in this test.
Exclusion criteria
Exclusion criteria: 1. 4 weeks before the trial had a clinically significant disease or had surgery; 2. Any laboratory test results are of clinical significance; 3. Drugs that are known to have an effect on an organ within 3 months or are currently in use; 4. People who have a history of drug allergy and are highly sensitive to environmental substances are allergic to Astragalus membranaceus and any of its ingredients or related drugs; 5. Susceptible to hypokalemia; 6. Congestive heart failure gastric ulcer glucose -6- phosphate dehydrogenase (G6PD) deficiency severe liver function damage severe renal impairment; 7. History of any other serious clinical disease or a disease of the cardiovascular system, endocrine system, or pulmonary, hematological, immunological, psychiatric, and metabolic disorders; 8. Recent cold; 9. Patients with active bleeding, diabetes, glaucoma and other diseases; 10. HIV positive test; 11. Hepatitis B surface antigen positive or hepatitis C test positive; l2. Ongoing treatment with any medical significance; 13. concomitant medication brfore 14 days prior; 14. History of drug abuse; 15. During the 3 months before and during the trial, the use of soft drugs such as marijuana or the use of hard drugs (such as cocaine, such as cocaine) during the year before and during the trial p)Participated in other drug trials within 3 months; 16. participate in blood donors in 3 months before the trial; 17. With coagulopathy or thromboembolic disease.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| pharmacokinetic parameters;bioavailability; | — |
Countries
China
Contacts
Public ContactZhirong Tan
Clinical Pharmacology Institution, Xiang Ya Hospital, Central South University
Outcome results
None listed